IL2 and melanoma: Additionally, Woods et al. showed that panobinostat (pan-HDACi) in melanoma increased the expression of MHC-I in cancer cells and increased the production of IL-2 and IFN-γ from CD4+ T cells, subsequently increasing the sensitivity to anti-PD-(L)1 therapy153,154.